NCT04821648 is a Phase 1 clinical trial of RJV001 in Submental Fat (SMF), sponsored by Rejuven Dermaceutical Co., Ltd..

Who is sponsoring NCT04821648?

NCT04821648 is sponsored by Rejuven Dermaceutical Co., Ltd..

What drugs are being tested in NCT04821648?

Interventions in NCT04821648: RJV001, Placebo.

What condition does NCT04821648 study?

NCT04821648 studies Submental Fat (SMF), Double Chin.

Is NCT04821648 still recruiting?

NCT04821648 is currently completed. Last updated 18 January 2022.

Last reviewed 2022-01-18 · How we verify

NCT04821648

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RJV001 Study in Adults Receiving Abdominoplasty

Completed Phase 1 Last updated 18 January 2022

What this trial tests

Phase 1 trial testing RJV001 in Submental Fat (SMF) in 18 participants. Completed in 16 December 2021.

Timeline

16 April 2021

Primary endpoint
16 December 2021

16 December 2021

Quick facts

Lead sponsor	Rejuven Dermaceutical Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	16 April 2021
Primary completion	16 December 2021
Estimated completion	16 December 2021
Sites	1 location across United States

Drugs / interventions tested

RJV001 — full drug profile →
Placebo

Conditions studied

Submental Fat (SMF) — all drugs for Submental Fat (SMF) →
Double Chin — all drugs for Double Chin →

Sponsor

Rejuven Dermaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Submental Fat (SMF) or Double Chin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, we are testing a new drug against submental fat (SMF), which is characterized with the accumulation of fat under the chin that often appears as a "double chin". The 2018 American Society for Dermatologic Surgery Consumer Survey on Cosmetic Dermatologic Procedures indicated that 73% of respondents were bothered by "excess fat under the chin/neck". This condition of loose or sagging skin under the chin may affect facial symmetry and attractiveness, which can lead to social embarrassment and a negative self-image in many patients. There is an insufficiency in effective drugs against SMF and double chin. Although an injectable small molecule can be used for improvement of double chin, but its side effects are evident and its cost is high. As such, there remains a real need to develop a cost-effective method to improve appearance of SMF and double chin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04821648 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rejuven Dermaceutical Co., Ltd.
Last refreshed: 18 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04821648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing